HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.